- Home
- NTLA vs BRAI Comparison
NTLA vs BRAI Comparison
Compare NTLA & BRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NTLA | BRAI |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | NTLA | BRAI |
|---|---|---|
| Price | $12.33 | $7.22 |
| Analyst Decision | Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $20.02 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 10.0K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $6.83 | $12.56 |
| 52 Week High | $28.24 | $32.32 |
Technical Indicators
Market Signals| Indicator | NTLA | BRAI |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 27.44 |
| Support Level | $11.19 | N/A |
| Resistance Level | $14.71 | $30.15 |
| Average True Range (ATR) | 1.18 | 1.99 |
| MACD | -0.27 | -0.69 |
| Stochastic Oscillator | 11.03 | 0.86 |
Price Performance
Historical ComparisonAbout NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.